Immune-glutamatergic dysfunction as a central mechanism of the autism spectrum disorders

Current Medicinal Chemistry

Volumn 16, Issue 2, 2009, Pages 157-170

  Blaylock, R L ^a   Strunecka, A ^b  

^a Belhaven College   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Autism spectrum disorders; Cytokines; Excitotoxicity; Fluoride; Glutamatergic neurotransmission; Inflammation; Mercury; Microglia

Indexed keywords

ALCOHOL; ALUMINUM; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ANTIOXIDANT; ASCORBIC ACID; ASPARTIC ACID; BARBITURIC ACID DERIVATIVE; COLECALCIFEROL; FLUORIDE; GLUTAMATE RECEPTOR; GLUTAMATE SODIUM; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; KETAMINE; LAMOTRIGINE; MAGNESIUM; MECOBALAMIN; MEMANTINE; MERCURY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE; PHENCYCLIDINE; PLACEBO; PYRIDOXINE; TUMOR NECROSIS FACTOR ALPHA;

AUTISM; BRAIN DEVELOPMENT; CELL MIGRATION; CLINICAL TRIAL; COGNITION; DIETARY INTAKE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EXCITOTOXICITY; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; LEARNING; MEMORY; MICROGLIA; MOTOR COORDINATION; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; POSTNATAL DEVELOPMENT; REVIEW; SEIZURE; BRAIN; CHILD; GENETICS; IMMUNOLOGY; IMMUNOPATHOLOGY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; POLLUTANT; PRESCHOOL CHILD; SYNAPTIC TRANSMISSION;

AUTISTIC DISORDER; BRAIN; CHILD; CHILD, PRESCHOOL; ENVIRONMENTAL POLLUTANTS; GLUTAMIC ACID; HUMANS; IMMUNE SYSTEM DISEASES; MICROGLIA; SYNAPTIC TRANSMISSION;

EID: 62349130905     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787002745     Document Type: Review

References (180)

1. Rice, C.E. Prevalence of autism spectrum disorders - autism and developmental disabilities monitoring network. Six sites, United States, 2000. MMWR Surveillance Summaries, 2007, 56, 1-11.
2. Bailey, A.; Le Couteur, A.; Gottesman, I.; Bolton, P.; Simonoff, E.; Yuzda, E.; Rutter, M. Autism as a strongly genetic disorder: Evidence from a British twin study. Psychol. Med., 1995, 25, 63-77.
3. Bethea, T.C.; Sikich L. Early pharmacological treatment of autism: A rationale for developmental treatment. Biol. Psychiatry, 2007, 61, 521-37.
4. Greenspan, S.I; Brazelton, T.B.; Cordero, J.; Solomon, R.; Bauman, M.L.; Robinson, R.; Shanker, S.; Breinbauer, C. Guidelines for early identification, screening, and clinical management of children with autism spectrum disorders. Pediatrics, 2008, 121, 828-30.
5. Purcell, A.E.; Jeon, O.H.; Zimmerman, A.W.; Blue, M.E.; Pevsner, J. Postmortem brain abnormalities of the glutamate neurotransmitter system in autism. Neurology, 2001, 57, 1618-28.
6. Blaylock, R.L. The central role of excitotoxicity in autism spectrum disorders. JAMA, 2003, 6, 10-22.
7. Blaylock, R.L. Excitotoxicity, a possible central mechanism in fluoride neurotoxicity. Fluoride, 2004, 37, 264-77.
8. McDougle, C.J.; Erickson, C.A.; Stigler, K.A.; Posey, D.J. Neurochemistry in the pathophysiology of autism. J. Clin. Psychiatry, 2005, 66, Suppl 10, 9-18.
9. Shinohe, A.; Hashimoto, K.; Nakamura, K.; Tsujii, M.; Iwata, Y.; Tsuchiya, K.J.; Sekine, Y.; Suda, S.; Suzuki, K.; Sugihara, G.; Matsuzaki, H.; Minabe, Y.; Sugiyama, T.; Kawai, M.; Iyo, M.; Takei, N.; Mori, N. Increased serum levels of glutamate in adult patients with autism. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30, 1472-77.
10. Chez, M.G.; Burton, Q.; Dowling, T.; Chang, M.; Khanna, P.; Kramer, C. Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: An observation of initial clinical response and maintenance tolerability. J. Child Neurol., 2007, 22, 574-79.
11. Hashimoto, K.; Shinohe, A.; Mori, N. Reply to: The hyperglutamatergic hypothesis of autism. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, Nov 13, (ahead of print).
12. Fatemi, S.H. The hyperglutamatergic hypothesis of autism. Prog Neuropsychopharmacol. Biol. Psychiatry, 2008, 32, 911
13. Aldred, S.; Moore, K.M.; Fitzgerald, M.; Waring, R.H. Plasma amino acid levels in children with autism and their families. J. Autism Dev. Disord., 2003, 33, 93-7.
14. Laurence, J.A.; Fatemi, S.H. Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects. Cerebellum, 2005, 4, 206-10.
15. Vargas, D.L.; Nascimbene, C.; Krishnan, C.; Zimmerman, A.W.; Pardo, C.A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann. Neurol., 2005, 57, 67-81.
16. Risch, N.; Spiker, D.; Lotspeich, L.; Nouri, N.; Hinds, D.; Hallmayer, J.; Kalaydjieva, L.; McCague, P.; Dimiceli, S.; Pitts, T.; Nguyen, L.; Yang, J.; Harper, C.; Thorpe, D.; Vermeer, S.; Young, H.; Hebert, J.; Lin, A.; Ferguson, J.; Chiotti, C.; Wiese-Slater, S.; Rogers, T.; Salmon, B.; Nicholas, P.; Petersen, P. B.; Pingree, C.; McMahon, W.; Wong, D. L.; Cavalli-Sforza, L. L.; Kraemer, H. C.; Myers, R. M. A genomic screen of autism: Evidence for a multilocus etiology. Am. J. Hum. Genet., 1999, 65, 493-507.
17. Gupta, A.R.; State, M.W. Recent advances in the genetics of autism. Biol. Psychiatry, 2007, 61, 429-37.
18. Philippe, A.; Martinez, M.; Guilloud-Bataille, M.; Gillberg, C.; Rastam, M.; Sponheim, E.; Coleman, M.; Zappella, M.; Aschauer, H.; Van Maldergem, L.; Penet, C.; Feingold, J.; Brice, A.; Leboyer, M. Genome-wide scan for autism susceptibility genes. Paris Autism Research International Sibpair Study. Hum. Mol. Genet., 1999, 8, 805-12.
19. Jamain, S.; Betancur, C.; Quach, H.; Philippe, A.; Fellous, M.; Giros, B.; Gillberg, C.; Leboyer, M.; Bourgeron, T. Linkage and association of the glutamate receptor 6 gene with autism. Mol. Psychiatry, 2002, 7, 302-10.
20. IMGSAC. Further characterization of the autism susceptibility locus AUTS1 on chromosome 7q. Hum. Mol. Genet., 2001, 10, 973-82.
21. Autism Research Consortium. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat. Genet., 2007, 3, 319-28.
22. Serajee, F.J.; Zhong, H.; Nabi, R.; Huq, A.H. The metabotropic glutamate receptor 8 gene at 7q31: Partial duplication and possible association with autism. J. Med. Genet., 2003, 40, e42.
23. Malherbe, P.; Kratzeisen, C.; Lundstrom, K.; Richards, J.G.; Faull, R.L.; Mutel, V. Cloning and functional expression of alternative spliced variants of the human metabotropic glutamate receptor 8. Brain Res. Mol. Brain Res., 1999, 67, 201-10.
24. Ramanathan, S.; Woodroffe, A.; Flodman, P. L.; Mays, L. Z.; Hanouni, M.; Modahl, C. B.; Steinberg-Epstein, R.; Bocian, M. E.; Spence, M. A.; Smith, M. A case of autism with an interstitial deletion on 4q leading to hemizygosity for genes encoding for glutamine and glycine neurotransmitter receptor sub-units (AMPA 2, GLRA3, GLRB) and neuropeptide receptors NPY1R, NPY5R. BMC Med. Genet., 2004, 5, 10.
25. Gamliel, I.; Yirmiya, N.; Sigman, M. The development of young siblings of children with autism from 4 to 54 months. J. Autism Dev. Disord., 2007, 37, 171-83.
26. Rapin, I. Autistic regression and disintegrative disorder: How important the role of epilepsy? Semin. Pediatr. Neurol., 1995, 2, 278-85.
27. Tordjman, S.; Anderson, G.M.; McBride, P.A.; Hertzig, M.E.; Snow, M.E.; Hall, L.M.; Ferrari, P.; Cohen, D.J. Plasma androgens in autism. J. Autism Dev. Disord., 1995, 25, 295-304.
28. Wakefield, A. J.; Murch, S. H.; Anthony, A.; Linnell, J.; Casson, D. M.; Malik, M.; Berelowitz, M.; Dhillon, A. P.; Thomson, M. A.; Harvey, P.; Valentine, A.; Davies, S. E.; Walker-Smith, J. A. Ileallymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet, 1998, 351, 637-41.
29. Lewine, J. D.; Andrews, R.; Chez, M.; Patil, A. A.; Devinsky, O.; Smith, M.; Kanner, A.; Davis, J. T.; Funke, M.; Jones, G.; Chong, B.; Provencal, S.; Weisend, M.; Lee, R. R.; Orrison, W. W., Jr. Magnetoencephalographic patterns of epileptiform activity in children with regressive autism spectrum disorders. Pediatrics, 1999, 104, 405-18.
30. Blaylock, R.L. Interaction of cytokines, excitotoxins, and reactive nitrogen and oxygen species in autism spectrum disorders. JAMA, 2003, 6, 21-35.
31. Palmen, S.J.; van Engeland, H.; Hof, P.R.; Schmitz, C. Neuropathological findings in autism. Brain, 2004, 127, 2572-83.
32. Moreno-Fuenmayor, H.; Borjas, L.; Arrieta, A.; Valera, V.; Socorro-Candanoza, L. Plasma excitatory amino acids in autism. Invest. Clin., 1996, 37, 113-28.
33. Chugani, D.C.; Sundram, B.S.; Behen, M.; Lee, M.L.; Moore, G.J. Evidence of altered energy metabolism in autistic children. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1999, 23, 635-41.
34. Fatemi, S.H.; Halt, A.R.; Stary, J.M.; Kanodia, R.; Schulz, S.C.; Realmuto, G.R. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol. Psychiatry, 2002, 52, 805-10.
35. Page, L. A.; Daly, E.; Schmitz, N.; Simmons, A.; Toal, F.; Deeley, Q.; Ambery, F.; McAlonan, G. M.; Murphy, K. C.; Murphy, D. G. In vivo 1H-magnetic resonance spectroscopy study of amygdalahippocampal and parietal regions in autism. Am. J. Psychiatry, 2006, 163, 2189-92.
36. Telfeian, A.E.; Federoff, H.J.; Leone, P.; During, M.J.; Williamson, A. Overexpression of GluR6 in rat hippocampus produces seizures and spontaneous nonsynaptic bursting in vitro. Neurobiol. Dis., 2000, 7, 362-74.
37. Zhang, H.; Liu, X.; Zhang, C.; Mundo, E.; Macciardi, F.; Grayson, D.R.; Guidotti, A.R.; Holden, J.J. Reelin gene alleles and susceptibility to autism spectrum disorders. Mol. Psychiatry, 2002, 7, 1012-17.
38. Yip, J.; Soghomonian, J.J.; Blatt, G.J. Decreased GAD67 mRNA levels in cerebellar Purkinje cells in autism: Pathophysiological implications. Acta Neuropathol., 2007, 113, 559-68.
39. Yip, J.; Soghomonian, J.J.; Blatt, G.J. Increased GAD67 mRNA expression in cerebellar interneurons in autism: Implications for Purkinje cell dysfunction. J. Neurosci. Res., 2008, 86, 525-30
40. Rigby, M.; Le Bourdelles, B.; Heavens, R.P.; Kelly, S.; Smith, D.; Butler, A.; Hammans, R.; Hills, R.; Xuereb, J.H.; Hill, R.G.; Whiting, P.J.; Sirinathsinghji, D.J. The messenger RNAs for the N-methyl-D-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain. Neuroscience, 1996, 73, 429-47.
41. Beattie, E.C.; Carroll, R.C.; Yu, X.; Morishita, W.; Yasuda, H.; von Zastrow, M.; Malenka, R.C. Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD. Nat. Neurosci., 2000, 3, 1291-300.
42. De Blasi, A.; Conn, P.J.; Pin, J.; Nicoletti, F. Molecular determinants of metabotropic glutamate receptor signaling. Trends Pharmacol. Sci., 2001, 22, 114-20.
43. Lavreysen, H.; Dautzenberg, F.M. Therapeutic Potential of Group III Metabotropic Glutamate Receptors. Curr. Med. Chem., 2008, 15, 671-84.
44. Novelli, A.; Reilly, J.A.; Lysko, P.G.; Henneberry, R.C. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res., 1988, 451, 205-12.
45. Nicholls, D.G.; Budd, S.L. Mitochondria and neuronal survival. Physiol. Rev., 2000, 80, 315-60.
46. Dölen, G.; Bear, M.F. Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J. Physiol., 2008, 586, 1503-08.
47. Seal, R.P.; Amara, S.G. Excitatory amino acid transporters: A family in flux. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 431-56.
48. Furuta, A.; Rothstein, J.D.; Martin, L.J. Glutamate transporter protein subtypes are expressed differentially during rat CNS development. J. Neurosci., 1997, 17, 8363-75.
49. Tsai, V.W.; Scott, H.L.; Lewis, R.J.; Dodd, P.R. The role of group I metabotropic glutamate receptors in neuronal excitotoxicity in Alzheimer's disease. Neurotox. Res., 2005, 7, 125-41.
50. Martin-Ruiz, R.; Ugedo, L.; Honrubia, M.A.; Mengod, G.; Artigas, F. Control of serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus. J. Neurochem., 2001, 77, 762-75.
51. Olney, J.W. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science, 1969, 164, 719-21.
52. Beal, H.; Hyman, B.T.; Koroshertz, W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci., 1994, 17, 107-08.
53. Rothstein, J.D. Excitotoxicity hypothesis. Neurology, 1996, 47, S19-25; discussion S26.
54. Bar-Peled, O.; Ben-Hur, H.; Biegon, A.; Groner, Y.; Dewhurst, S.; Furuta, A.; Rothstein, J.D. Distribution of glutamate transporter subtypes during human brain development. J. Neurochem., 1997, 69, 2571-80.
55. Schlett, K. Glutamate as a modulator of embryonic and adult neurogenesis. Curr. Top Med. Chem., 2006, 6, 949-60.
56. Olney, J.W. New insights and new issues in developmental neurotoxicology. Neurotoxicology, 2002, 23, 659-68.
57. Marret, S.; Gressens, P.; Evrard, P. Arrest of neuronal migration by excitatory amino acids in hamster developing brain. Proc. Natl. Acad. Sci. USA, 1996, 93, 15463-8.
58. Carper, R.A.; Courchesne, E. Inverse correlation between frontal lobe and cerebellum sizes in children with autism. Brain, 2000, 123 (Pt 4), 836-44.
59. Fatemi, S.H.; Halt, A.R.; Realmuto, G.; Earle, J.; Kist, D.A.; Thuras, P.; Merz, A. Purkinje cell size is reduced in cerebellum of patients with autism. Cell Mol. Neurobiol., 2002, 22, 171-5.
60. Komuro, H.; Yacubova, E. Recent advances in cerebellar granule cell migration. Cell. Mol. Life Sci., 2003, 60, 1084-98.
61. Komuro, H.; Rakic, P. Modulation of neuronal migration by NMDA receptors. Science, 1993, 260, 95-7.
62. Komuro, H.; Rakic, P. Orchestration of neuronal migration by activity of ion channels, neurotransmitter receptors, and intracellular Ca2+ fluctuations. J. Neurobiol., 1998, 37, 110-30.
63. Shen, W.; Slaughter, M.M. A non-excitatory paradigm of glutamate toxicity. J. Neurophysiol., 2002, 87, 1629-34.
64. D'Aversa, T.G.; Yu, K.O.; Berman, J.W. Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein Tat. J. Neurovirol., 2004, 10, 86-97.
65. Farber, K.; Kettenmann, H. Physiology of microglial cells. Brain Res. Brain Res. Rev., 2005, 48, 133-43.
66. Dziegielewska, K.M.; Moller, J.E.; Potter, A.M.; Ek, J.; Lane, M.A.; Saunders, N.R. Acute-phase cytokines IL-1beta and TNF-alpha in brain development. Cell Tissue Res., 2000, 299, 335-45
67. Koenig, H.; Trout, J.J.; Goldstone, A.D.; Lu, C.Y. Capillary NMDA receptors regulate blood-brain barrier function and breakdown. Brain Res., 1992, 588, 297-303.
68. Lagrange, P.; Romero, I.A.; Minn, A.; Revest, P.A. Transendothelial permeability changes induced by free radicals in an in vitro model of the blood-brain barrier. Free Radic. Biol. Med., 1999, 27, 667-72.
69. Verity, M.A. Oxidative damage and repair in the developing nervous system. Neurotoxicology, 1994, 15, 81-91.
70. Carlsson, M.L. Hypothesis: Is infantile autism a hypoglutamatergic disorder? Relevance of glutamate - serotonin interactions for pharmacotherapy. J. Neural. Transm., 1998, 105, 525-35.
71. Ben-Ari, Y. Limbic seizure and brain damage produced by kainic acid: mechanisms and relevance to human temporal lobe epilepsy. Neuroscience, 1985, 14, 375-403.
72. Olney, J.W.; Collins, R.C.; Sloviter, R.S. Excitotoxic mechanisms of epileptic brain damage. Adv. Neurol., 1986, 44, 857-77.
73. Tuchman, R.F.; Rapin, I. Regression in pervasive developmental disorders: Seizures and epileptiform electroencephalogram correlates. Pediatrics, 1997, 99, 560-6.
74. Meldrum, B.S.; Rogawski, M.A. Molecular targets for antiepileptic drug development. Neurotherapeutics, 2007, 4, 18-61.
75. Baumeister, F.A.; Gsell, W.; Shin, Y.S.; Egger, J. Glutamate in pyridoxine-dependent epilepsy: Neurotoxic glutamate concentration in the cerebrospinal fluid and its normalization by pyridoxine. Pediatrics, 1994, 94, 318-21.
76. Johnston, M.V. Neurotransmitters and vulnerability of the developing brain. Brain Dev., 1995, 17, 301-6.
77. Belmonte, M.K.; Allen, G.; Beckel-Mitchener, A.; Boulanger, L.M.; Carper, R.A.; Webb, S.J. Autism and abnormal development of brain connectivity. J. Neurosci., 2004, 24, 9228-31.
78. Yu, T.; Zhao, Y.; Shi, W.; Ma, R.; Yu, L. Effects of maternal oral administration of monosodium glutamate at a late stage of pregnancy on developing mouse fetal brain. Brain Res., 1997, 747, 195-206.
79. Nacher, J.; McEwen, B.S. The role of N-methyl-D-asparate receptors in neurogenesis. Hippocampus, 2006, 16, 267-70.
80. Cohly, H.H.; Panja, A. Immunological findings in autism. Int. Rev. Neurobiol., 2005, 71, 317-41.
81. Ashwood, P.; Wakefield, A.J. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J. Neuroimmunol., 2006, 173, 126-34.
82. Ashwood, P.; Wills, S.; Van de Water, J. The immune response in autism: a new frontier for autism research. J. Leukoc. Biol., 2006, 80, 1-15.
83. Gadient, R.A.; Otten, U. Expression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) mRNAs in rat brain during postnatal development. Brain Res., 1994, 637, 10-14.
84. Saliba, E.; Henrot, A. Inflammatory mediators and neonatal brain damage. Biol. Neonate, 2001, 79, 224-7.
85. Vallieres, L.; Campbell, I.L.; Gage, F.H.; Sawchenko, P.E. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J. Neurosci., 2002, 22, 486-92.
86. Ekdahl, C.T.; Claasen, J.H.; Bonde, S.; Kokaia, Z.; Lindvall, O. Inflammation is detrimental for neurogenesis in adult brain. Proc. Natl. Acad. Sci. USA, 2003, 100, 13632-37.
87. Singh, V.K.; Warren, R.; Averett, R.; Ghaziuddin, M. Circulating autoantibodies to neuronal and glial filament proteins in autism. Pediatr. Neurol., 1997, 17, 88-90.
88. Singh, V.K.; Lin, S.X.; Newell, E.; Nelson, C. Abnormal measlesmumps-rubella antibodies and CNS autoimmunity in children with autism. J. Biomed. Sci., 2002, 9, 359-64.
89. Hamberger, A.; Gillberg, C.; Palm, A.; Hagberg, B. Elevated CSF glutamate in Rett syndrome. Neuropediatrics, 1992, 23, 212-3.
90. Panegyres, P.K.; Hughes, J. The neuroprotective effects of the recombinant interleukin-1 receptor antagonist rhIL-1ra after excitotoxic stimulation with kainic acid and its relationship to the amyloid precursor protein gene. J. Neurol. Sci., 1998, 154, 123-32.
91. Zimmerman, A.W.; Jyonouchi, H.; Comi, A.M.; Connors, S.L.; Milstien, S.; Varsou, A.; Heyes, M.P. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr. Neurol., 2005, 33, 195-201.
92. Yang, L.; Lindholm, K.; Konishi, Y.; Li, R.; Shen, Y. Target depletion of distinct tumor necrosis factor receptor subtypes reveals hippocampal neuron death and survival through different signal transduction pathways. J. Neurosci., 2002, 22, 3025-32.
93. Takeuchi, H.; Jin, S.; Wang, J.; Zhang, G.; Kawanokuchi, J.; Kuno, R.; Sonobe, Y.; Mizuno, T.; Suzumura, A. Tumor necrosis factor-alpha induces neurotoxicity via glutamate release from hemichannels of activated microglia in an autocrine manner. J. Biol. Chem., 2006, 281, 21362-8.
94. Qiu, Z.; Sweeney, D.D.; Netzeband, J.G.; Gruol, D.L. Chronic interleukin-6 alters NMDA receptor-mediated membrane responses and enhances neurotoxicity in developing CNS neurons. J. Neurosci., 1998, 18, 10445-56.
95. Combrinck, M.I.; Perry, V.H.; Cunningham, C. Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease. Neuroscience, 2002, 112, 7-11.
96. Buller, K.M.; Day, T.A. Systemic administration of interleukin-1beta activates select populations of central amygdala afferents. J. Comp. Neurol., 2002, 452, 288-96.
97. Kim, W.G.; Mohney, R.P.; Wilson, B.; Jeohn, G.H.; Liu, B.; Hong, J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: Role of microglia. J. Neurosci., 2000, 20, 6309-16.
98. Perry, V.H.; Newman, T.A.; Cunningham C. The impact of systemic infection on the progression of neurodegenerative disease. Nat. Rev. Neurosci., 2003, 4, 103-12.
99. Cunningham, C.; Deacon, R.; Wells, H.; Boche, D.; Waters, S.; Diniz, C.P.; Scott, H.; Rawlins, J.N.; Perry, V.H. Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease. Eur. J. Neurosci., 2003, 17, 2147-55.
100. Lemstra, A.W.; Groen in't Woud, J.C.; Hoozemans, J.J.; van Haastert, E.S.; Rozemuller, A.J.; Eikelenboom, P.; van Gool, W.A. Microglia activation in sepsis: A case-control study. J. Neuroinflammation, 2007, 4, 4.
101. Katayama, Y.; Hotta, H.; Nishimura, A.; Tatsuno, Y.; Homma, M. Detection of measles virus nucleoprotein mRNA in autopsied brain tissues. J. Gen. Virol., 1995, 76 (Pt 12), 3201-4.
102. Charleston, J.S.; Body, R.L.; Bolender, R.P.; Mottet, N.K.; Vahter M.E.; Burbacher, T.M. Changes in the number of astrocytes and microglia in the thalamus of the monkey Macaca fascicularis following long-term subclinical methylmercury exposure. Neurotoxicology, 1996, 17, 127-38.
103. Vahter, M.; Akesson, A.; Lind, B.; Bjors, U.; Schutz, A.; Berglund, M. Longitudinal study of methylmercury and inorganic mercury in blood and urine of pregnant and lactating women, as well as in umbilical cord blood. Environ. Res., 2000, 84, 186-94.
104. Burbacher, T.M.; Rodier, P.M.; Weiss, B. Methylmercury developmental neurotoxicity: A comparison of effects in humans and animals. Neurotoxicol. Teratol., 1990, 12, 191-202.
105. Burbacher, T.M.; Shen, D.D.; Liberato, N.; Grant, K.S.; Cernichiari, E.; Clarkson, T. Comparison of blood and brain mercury levels in infant monkeys exposed to methylmercury or vaccines containing thimerosal. Environ. Health Perspect., 2005, 113, 1015-21.
106. Vojdani, A.; Campbell, A.W.; Anyanwu, E.; Kashanian, A.; Bock, K.; Vojdani, E. Antibodies to neuron-specific antigens in children with autism: Possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J. Neuroimmunol., 2002, 129, 168-77.
107. Vojdani, A.; O'Bryan, T.; Green, J.A.; McCandless, J.; Woeller, K.N.; Vojdani, E.; Nourian, A.A.; Cooper, E.L. Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism. Nutr. Neurosci., 2004, 7, 151-61.
108. Hida, S.; Miura, N.N.; Adachi, Y.; Ohno, N. Effect of Candida albicans cell wall glucan as adjuvant for induction of autoimmune arthritis in mice. J. Autoimmun., 2005, 25, 93-101.
109. Hida, S.; Nagi-Miura, N.; Adachi, Y.; Ohno, N. Beta-glucan derived from zymosan acts as an adjuvant for collagen-induced arthritis. Microbiol. Immunol., 2006, 50, 453-61.
110. Olney, J.W. Glutamate, a neurotoxic transmitter. J. Child Neurol., 1989, 4, 218-26.
111. Plaitakis, A.; Flessas, P.; Natsiou, A.B.; Shashidharan, P. Glutamate dehydrogenase deficiency in cerebellar degenerations: Clinical, biochemical and molecular genetic aspects. Can. J. Neurol. Sci., 1993, 20 Suppl 3, S109-16.
112. Olney, J.W.; Sharpe, L.G.; Feigin, R.D. Glutamate-induced brain damage in infant primates. J. Neuropathol. Exp. Neurol., 1972, 31, 464-88.
113. Frieder, B.; Grimm, V.E. Prenatal monosodium glutamate (MSG) treatment given through the mother's diet causes behavioral deficits in rat offspring. Int. J. Neurosci., 1984, 23, 117-26
114. Frieder, B.; Grimm, V.E. Prenatal monosodium glutamate causes long-lasting cholinergic and adrenergic changes in various brain regions. J. Neurochem., 1987, 48, 1359-65.
115. Sakamoto, M.; Nakano, A. Comparison of mercury accumulation among the brain, liver, kidney, and the brain regions of rats administered methylmercury in various phases of postnatal development. Bull. Environ. Contam. Toxicol., 1995, 55, 588-96.
116. Mitani, A.; Watanabe, M.; Kataoka, K. Functional change of NMDA receptors related to enhancement of susceptibility to neurotoxicity in the developing pontine nucleus. J. Neurosci., 1998, 18, 7941-52.
117. Bawari, M.; Babu, G.N.; Ali, M.M.; Misra, U.K. Effect of neonatal monosodium glutamate on lipid peroxidation in adult rat brain. Neuroreport, 1995, 6, 650-2.
118. Singh, K.; Ahluwalia, P. Studies on the effect of monosodium glutamate [MSG] administration on some antioxidant enzymes in the arterial tissue of adult male mice. J. Nutr. Sci. Vitaminol. (Tokyo), 2003, 49, 145-8.
119. Martinez-Contreras, A.; Huerta, M.; Lopez-Perez, S.; Garcia-Estrada, J.; Luquin, S.; Beas Zarate, C. Astrocytic and microglia cells reactivity induced by neonatal administration of glutamate in cerebral cortex of the adult rats. J. Neurosci. Res., 2002, 67, 200-10.
120. Beas-Zarate, C.; Perez-Vega, M.; Gonzalez-Burgos, I. Neonatal exposure to monosodium L-glutamate induces loss of neurons and cytoarchitectural alterations in hippocampal CA1 pyramidal neurons of adult rats. Brain Res., 2002, 952, 275-81.
121. Kubo, T.; Kohira, R.; Okano, T.; Ishikawa, K. Neonatal glutamate can destroy the hippocampal CA1 structure and impair discrimination learning in rats. Brain Res., 1993, 616, 311-4.
122. Wong, P.T.; Neo, L.H.; Teo, W.L.; Feng, H.; Xue, Y.D.; Loke, W.H. Deficits in water escape performance and alterations in hippocampal cholinergic mechanisms associated with neonatal monosodium glutamate treatment in mice. Pharmacol. Biochem. Behav., 1997, 57, 383-8.
123. Dubovicky, M.; Tokarev, D.; Skultetyova, I.; Jezova, D. Changes of exploratory behaviour and its habituation in rats neonatally treated with monosodium glutamate. Pharmacol. Biochem. Behav., 1997, 56, 565-9.
124. Yan, H.D.; Ji-qun, C.; Ishihara, K.; Nagayama, T.; Serikawa, T.; Sasa, M. Separation of antiepileptogenic and antiseizure effects of levetiracetam in the spontaneously epileptic rat (SER). Epilepsia, 2005, 46, 1170-7.
125. Wilson, B.M.; Cox, C.L. Absence of metabotropic glutamate receptor-mediated plasticity in the neocortex of fragile X mice. Proc. Natl. Acad. Sci. USA, 2007, 104, 2454-9.
126. Chang, S.; Bray, S.M.; Li, Z.; Zarnescu, D.C.; He, C.; Jin, P.; Warren, S.T. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat. Chem. Biol., 2008, 4, 256-63.
127. Geier, D.A.; Geier, M.R. A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic disorders. Neuroendocrinol. Lett., 2006, 27, 833-8.
128. Geier, D.A.; Geier, M.R. A prospective assessment of porphyrins in autistic disorders: A potential marker for heavy metal exposure. Neurotox. Res., 2006, 10, 57-64.
129. Sager, P.R.; Aschner, M.; Rodier, P.M. Persistent, differential alterations in developing cerebellar cortex of male and female mice after methylmercury exposure. Brain Res., 1984, 314, 1-11.
130. Choi, B.H. The effects of methylmercury on the developing brain. Prog. Neurobiol., 1989, 32, 447-70.
131. Park, S.T.; Lim, K.T.; Chung, Y.T.; Kim, S.U. Methylmercury-induced neurotoxicity in cerebral neuron culture is blocked by antioxidants and NMDA receptor antagonists. Neurotoxicology, 1996, 17, 37-45.
132. Miyamoto, K.; Nakanishi, H.; Moriguchi, S.; Fukuyama, N.; Eto, K.; Wakamiya, J.; Murao, K.; Arimura, K.; Osame, M. Involvement of enhanced sensitivity of N-methyl-D-aspartate receptors in vulnerability of developing cortical neurons to methylmercury neurotoxicity. Brain Res., 2001, 901, 252-8.
133. Sorg, O.; Schilter, B.; Honegger, P.; Monnet-Tschudi, F. Increased vulnerability of neurones and glial cells to low concentrations of methylmercury in a prooxidant situation. Acta Neuropathol., 1998, 96, 621-7.
134. Behan, W.M.; Stone, T.W. Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists. Br. J. Pharmacol., 2002, 135, 1435-42.
135. Chauhan, A.; Chauhan, V.; Brown, W.T.; Cohen, I. Oxidative stress in autism: Increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin - the antioxidant proteins. Life Sci., 2004, 75, 2539-49.
136. Ming, X.; Stein, T.P.; Brimacombe, M.; Johnson,W.G.; Lambert, G.H.; Wagner, G.C. Increased excretion of a lipid peroxidation biomarker in autism. Prostaglandins Leukot. Essent. Fatty Acids, 2005, 73, 379-84.
137. Brown, G.C.; Bal-Price, A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria. Mol. Neurobiol., 2003, 27, 325-55.
138. Hornig, M.; Chian, D.; Lipkin, W.I. Neurotoxic effects of postnatal thimerosal are mouse strain dependent. Mol. Psychiatry, 2004, 9, 833-45.
139. Brookes, N. Specificity and reversibility of the inhibition by HgCl2 of glutamate transport in astrocyte cultures. J. Neurochem., 1988, 50, 1117-22.
140. Inage, Y.W.; Itoh, M.; Wada, K.; Takashima, S. Expression of two glutamate transporters, GLAST and EAAT4, in the human cerebellum: Their correlation in development and neonatal hypoxicischemic damage. J. Neuropathol. Exp. Neurol., 1998, 57, 554-62.
141. Juarez, B.I.; Martinez, M.L.; Montante, M.; Dufour, L.; Garcia, E.; Jimenez-Capdeville, M.E. Methylmercury increases glutamate extracellular levels in frontal cortex of awake rats. Neurotoxicol. Teratol., 2002, 24, 767-71.
142. Ou, Y.C.; White, C.C.; Krejsa, C.M.; Ponce, R.A.; Kavanagh, T.J.; Faustman, E.M. The role of intracellular glutathione in methylmercury-induced toxicity in embryonic neuronal cells. Neurotoxicology, 1999, 20, 793-804.
143. Shanker, G.; Syversen, T.; Aschner, J.L.; Aschner, M. Modulatory effect of glutathione status and antioxidants on methylmercury-induced free radical formation in primary cultures of cerebral astrocytes. Brain Res. Mol. Brain Res., 2005, 137, 11-22.
144. Yokel, R.A.; Florence, R.L. Aluminum bioavailability from the approved food additive leavening agent acidic sodium aluminum phosphate, incorporated into a baked good, is lower than from water. Toxicology, 2006, 227, 86-93.
145. Speerhas, R.A.; Seidner, D.L. Measured versus estimated aluminum content of parenteral nutrient solutions. Am. J. Health Syst. Pharm., 2007, 64, 740-6.
146. Campbell, A. The role of aluminum and copper on neuroinflammation and Alzheimer's disease. J. Alzheimers Dis., 2006, 10, 165-72.
147. Savory, J.; Herman, M.M.; Ghribi, O. Mechanisms of aluminum-induced neurodegeneration in animals: Implications for Alzheimer's disease. J. Alzheimers Dis., 2006, 10, 135-44.
148. Mundy, W.R.; Freudenrich, T.M.; Kodavanti, P.R. Aluminum potentiates glutamate-induced calcium accumulation and iron-induced oxygen free radical formation in primary neuronal cultures. Mol. Chem. Neuropathol., 1997, 32, 41-57.
149. Mullenix, P.J.; Denbesten, P.K.; Schunior, A.; Kernan, W.J. Neurotoxicity of sodium fluoride in rats. Neurotoxicol. Teratol., 1995, 17, 169-77.
150. Strunecka, A.; Strunecky O.; Patocka J. Fluoride plus aluminum: Useful tools in laboratory investigations, but messengers of false information. Physiol. Res., 2002, 51, 557-64.
151. Strunecka, A.; Patocka, J.; Blaylock, R.L.; Chinoy, N.J. Fluoride interactions: From molecules to disease. Curr. Signal Transd. Ther., 2007, 2, 190-213.
152. Luke, J. Fluoride deposition in the aged human pineal gland. Caries Res., 2001, 35, 125-08.
153. Tordjman, S.; Anderson, G.M.; Pichard, N.; Charbuy, H.; Touitou, Y. Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. Biol. Psychiatry, 2005, 57, 134-8.
154. Pandi-Perumal, S.R.; Smits, M.; Spence, W.; Srinivasan, V.; Cardinali, D.P.; Lowe, A.D.; Kayumov, L. Dim light melatonin onset (DLMO): A tool for the analysis of circadian phase in human sleep and chronobiological disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31, 1-11.
155. Tauman, R.; Zisapel, N.; Laudon, M.; Nehama, H.; Sivan, Y. Melatonin production in infants. Pediatr. Neurol., 2002, 26, 379-82.
156. Stigler, K.A.; Desmond, L.A.; Posey, D.J.; Wiegand, R.E.; McDougle, C.J. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J. Child Adolesc. Psychopharmacol., 2004, 14, 49-56.
157. Belsito, K.M.; Law, P.A.; Kirk, K.S.; Landa, R.J.; Zimmerman, A.W. Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. J. Autism Dev. Disord., 2001, 31, 175-81.
158. Erickson, C.A.; Posey, D.J.; Stigler, K.A.; Mullett, J.; Katschke, A.R.; McDougle, C.J. A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl)., 2007, 191, 141-7.
159. Mazza, M.; Pomponi, M.; Janiri, L.; Bria, P.; Mazza, S. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31, 12-26.
160. Bourre, J.M. Effects of nutrients (in food) on the structure and function of the nervous system: Update on dietary requirements for brain. Part 1: Micronutrients. J. Nutr.. Health Aging, 2006, 10, 377-85.
161. Filipek, P.A.; Juranek, J.; Nguyen, M.T.; Cummings, C.; Gargus, J.J. Relative carnitine deficiency in autism. J. Autism Dev. Disord., 2004, 34, 615-23.
162. Wong, H.H.; Smith, R.G. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J. Autism Dev. Disord., 2006, 36, 901-9.
163. Jones, T.W.; Borg, W.P.; Boulware, S.D.; McCarthy, G.; Sherwin, R.S.; Tamborlane, W.V. Enhanced adrenomedullary response and increased susceptibility to neuroglycopenia: Mechanisms underlying the adverse effects of sugar ingestion in healthy children. J. Pediatr., 1995, 126, 171-7.
164. Dolske, M.C.; Spollen, J.; McKay, S.; Lancashire, E.; Tolbert, L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog. Neuropsychopharmacol. Biol. Psychiatry, 1993, 17, 765-74.
165. Kheir-Eldin, A.A.; Motawi, T.K.; Gad, M.Z.; Abd-ElGawad, H.M. Protective effect of vitamin E, beta-carotene and N-acetylcysteine from the brain oxidative stress induced in rats by lipopolysaccharide. Int. J. Biochem. Cell Biol., 2001, 33, 475-82.
166. Akaike, A.; Tamura, Y.; Sato, Y.; Yokota, T. Protective effects of a vitamin B12 analog, methylcobalamin, against glutamate cytotoxicity in cultured cortical neurons. Eur. J. Pharmacol., 1993, 241, 1-6.
167. Rimland, B. High dose vitamin B6 and magnesium in treating autism: response to study by Findling et al. J. Autism Dev. Disord., 1998, 28, 581-2.
168. Eyles, D.W.; Smith, S.; Kinobe, R.; Hewison, M.; McGrath, J.J. Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J. Chem. Neuroanat., 2005, 29, 21-30.
169. Taniura, H.; Ito, M.; Sanada, N.; Kuramoto, N.; Ohno, Y.; Nakamichi, N.; Yoneda, Y. Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. J. Neurosci. Res., 2006, 83, 1179-89.
170. Cannell, J.J. Autism and vitamin D. Med. Hypotheses, 2008, 70, 750-9.
171. Lainhart, J.E.; Bigler, E.D.; Bocian, M.; Coon, H.; Dinh, E.; Dawson, G.; Deutsch, C.K.; Dunn, M.; Estes, A.; Tager-Flusberg, H.; Folstein, S.; Hepburn, S.; Hyman, S.; McMahon, W.; Minshew, N.; Munson, J.; Osann, K.; Ozonoff, S.; Rodier, P.; Rogers, S.; Sigman, M.; Spence, M.A.; Stodgell, C.J.; Volkmar, F. Head circumference and height in autism: A study by the Collaborative Program of Excellence in Autism. Am. J. Med. Genet. A., 2006, 140, 2257-74.
172. Neveu, I.; Naveilhan, P.; Menaa, C.; Wion, D.; Brachet, P.; Garabedian, M. Synthesis of 1,25-dihydroxyvitamin D3 by rat brain macrophages in vitro. J. Neurosci. Res., 1994, 38, 214-20.
173. Lefebvre d'Hellencourt, C.; Montero-Menei, C.N.; Bernard, R.; Couez, D. Vitamin D3 inhibits proinflammatory cytokines and nitric oxide production by the EOC13 microglial cell line. J. Neurosci. Res., 2003, 71, 575-82.
174. Nataf, S.; Garcion, E.; Darcy, F.; Chabannes, D.; Muller, J.Y.; Brachet, P. 1,25 Dihydroxyvitamin D3 exerts regional effects in the central nervous system during experimental allergic encephalomyelitis. J. Neuropathol. Exp. Neurol., 1996, 55, 904-14.
175. Cantorna, M.T.; Hayes, C.E.; DeLuca, H.F. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA, 1996, 93, 7861-4.
176. Cantorna, M.T.; Zhu, Y.; Froicu, M.; Wittke, A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am. J. Clin. Nutr., 2004, 80, 1717S-20S.
177. Wang, Y.; Chiang, Y.H.; Su, T.P.; Hayashi, T.; Morales, M.; Hoffer, B.J.; Lin, S.Z. Vitamin D(3) attenuates cortical infarction induced by middle cerebral arterial ligation in rats. Neuropharmacology, 2000, 39, 873-80.
178. Blaylock, R.L. Phytonutrients and metabolic stimulants as protection against neurodegeneration and excitotoxicity. JAMA, 2000, 2, 30-41.
179. Garstang, J.; Wallis, M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev., 2006, 32, 585-9.
180. Anderson, G.M. The potential role for emergence in autism. Autism Res., 2008, 1, 18-30.